MedTrace Logo

Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin Lymphoma

NCT01569204 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2018-10-29

No results posted yet for this study

Summary

The Purpose of this trial is:

* to determine complete response rate (CRR) after six cycles of chemotherapy
* to determine complete remission rate (CR/CRr) as final treatment outcome after completion of treatment

Conditions

Interventions

DRUG

Etoposide

DRUG

Cyclophosphamide

DRUG

Doxorubicin

DRUG

Prednisone

DRUG

Procarbazine

DRUG

Dexamethasone

DRUG

Dacarbazine

DRUG

Brentuximab Vedotin

Sponsors & Collaborators

  • University of Cologne

    lead OTHER

Principal Investigators

  • Peter Borchmann, Prof. · University of Cologne, German Hodgkin Study Group

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-10-31
Primary Completion
2014-03-31
Completion
2017-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01569204 on ClinicalTrials.gov